12 results
PRER14A
GLSHQ
Gelesis Holdings, Inc.
7 Sep 23
Preliminary revised proxy
4:03pm
, in connection with its approval of Qsymia, the FDA required a Risk Evaluation and Mitigation Strategy program to inform prescribers and women
PREM14A
GLSHQ
Gelesis Holdings, Inc.
24 Jul 23
Preliminary proxy related to merger
9:47pm
to inform prescribers and women with the potential to become pregnant about the increased risk of congenital malformation in infants exposed to Qsymia
424B3
GLSHQ
Gelesis Holdings, Inc.
6 Sep 22
Prospectus supplement
4:53pm
and Mitigation Strategy, or REMS, program to inform prescribers and women with the potential to become pregnant about the increased risk of congenital
424B3
9gokofwvnmcm0xn bll
8 Jun 22
Prospectus supplement
4:21pm
425
x6l13q
28 Oct 21
Business combination disclosure
7:17am
S-4
mau54zmeu3fawcsi4m
10 Aug 21
Registration of securities issued in business combination transactions
5:24pm
- Prev
- 1
- Next